![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
威尼托克拉克斯 (Venetoclax Plus) 作为新诊断的Ph阴性B细胞急性淋巴细胞白血病的第一线治疗方法
Yutian Lei1, Xiaoli Zhao1, Huijun Huang1
1Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Blood and lymphatic cancer : targets and therapy
|November 11, 2025
概括
一个14天的blinatumomab-venetoclax疗法在新诊断的费城染色体阴性B细胞急性淋巴细胞白血病 (B-ALL) 中实现了高缓解率. 这种诱导疗法在不适合的患者中表现出良好的耐受性和快速MRD清除.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 新诊断的费城染色体阴性B细胞急性淋巴细胞白血病 (B-ALL) presents治疗挑战,特别是在不适合的患者.
- 在这种患者群体中,标准的诱导疗法可能具有低于最佳的疗效或耐受性.
研究的目的:
- 评估一种新的14天布利纳图马布-维内托克拉克斯 (BV) 治疗方案的疗效和安全性,作为新诊断的Ph阴性B-ALL的诱导疗法.
- 评估完全缓解率 (CR) 和最小残留疾病 (MRD) 的负面性.
- 确定不适合患者BV治疗方案的耐受性和安全性.
主要方法:
- 十三名新诊断的Ph阴性B-ALL不适合患者接受了为期14天的BV治疗方案.
- 威尼托克拉克斯是以不断升级的剂量给予的,其次是布利纳图马布.
- 进行骨髓评估,以通过流式细胞计量评估CR和MRD负面性.
主要成果:
- 在一轮治疗后,BV疗法实现了92.3% (12/13) 的CR率.
- 所有可评估的患者 (11/12) 在第21天实现了MRD阴性,表明深度缓解.
- 该疗法一般耐受良好,有可管理的毒性,包括细胞因子释放综合征和血液学不良事件.
结论:
- 14天的BV疗法是新诊断的Ph-阴性B-ALL的有效诱导疗法,可诱导快速和深度缓解.
- 该疗法表现出可管理的安全性,适合不适合患者.
- 维内托克拉克斯对T细胞的协同激活可能有助于观察到的增强疗效.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K